Alnylam Pharmaceuticals Inc (ALNY)
246.80
-1.99
(-0.80%)
USD |
NASDAQ |
Nov 21, 16:00
249.68
+2.88
(+1.17%)
After-Hours: 20:00
Alnylam Pharmaceuticals Enterprise Value: 30.08B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 30.08B |
| November 20, 2024 | 30.33B |
| November 19, 2024 | 28.46B |
| November 18, 2024 | 28.20B |
| November 15, 2024 | 28.63B |
| November 14, 2024 | 31.51B |
| November 13, 2024 | 32.37B |
| November 12, 2024 | 32.93B |
| November 11, 2024 | 34.33B |
| November 08, 2024 | 34.03B |
| November 07, 2024 | 33.35B |
| November 06, 2024 | 33.46B |
| November 05, 2024 | 32.46B |
| November 04, 2024 | 33.06B |
| November 01, 2024 | 33.57B |
| October 31, 2024 | 32.63B |
| October 30, 2024 | 34.55B |
| October 29, 2024 | 34.96B |
| October 28, 2024 | 35.25B |
| October 25, 2024 | 34.98B |
| October 24, 2024 | 36.08B |
| October 23, 2024 | 36.23B |
| October 22, 2024 | 36.44B |
| October 21, 2024 | 35.87B |
| October 18, 2024 | 36.37B |
| Date | Value |
|---|---|
| October 17, 2024 | 36.48B |
| October 16, 2024 | 36.97B |
| October 15, 2024 | 35.27B |
| October 14, 2024 | 34.75B |
| October 11, 2024 | 34.88B |
| October 10, 2024 | 34.14B |
| October 09, 2024 | 33.15B |
| October 08, 2024 | 33.18B |
| October 07, 2024 | 32.61B |
| October 04, 2024 | 32.77B |
| October 03, 2024 | 32.97B |
| October 02, 2024 | 33.23B |
| October 01, 2024 | 33.81B |
| September 30, 2024 | 33.68B |
| September 27, 2024 | 33.69B |
| September 26, 2024 | 33.65B |
| September 25, 2024 | 33.41B |
| September 24, 2024 | 33.19B |
| September 23, 2024 | 33.30B |
| September 20, 2024 | 33.56B |
| September 19, 2024 | 33.87B |
| September 18, 2024 | 33.47B |
| September 17, 2024 | 33.63B |
| September 16, 2024 | 33.11B |
| September 13, 2024 | 32.45B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
8.993B
Minimum
Mar 12 2020
36.97B
Maximum
Oct 16 2024
19.59B
Average
18.60B
Median
Dec 03 2021
Enterprise Value Benchmarks
| Pfizer Inc | 199.35B |
| BridgeBio Pharma Inc | 5.857B |
| Gilead Sciences Inc | 129.99B |
| Johnson & Johnson | 389.84B |
| Regeneron Pharmaceuticals Inc | 74.00B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -111.57M |
| Revenue (Quarterly) | 500.92M |
| Total Expenses (Quarterly) | 577.82M |
| EPS Diluted (Quarterly) | -0.87 |
| Gross Profit Margin (Quarterly) | 82.85% |
| Profit Margin (Quarterly) | -22.27% |
| Earnings Yield | -1.06% |
| Normalized Earnings Yield | -0.7449 |